|
|
Analysis of components and targets of Ganjiang Huangqin Huanglian Renshen Decoction in the treatment of gastric adenocarcinoma based on WGCNA and molecular docking#br# |
SUN Qian1 YANG Meizi2 LUAN Jixin3 LI Sen4 ZHANG Fan1 |
1.Department of Clinical Pharmacy, Liaocheng People’s Hospital, Shandong Province, Liaocheng 252000, China;
2.Department of Pharmacology, Binzhou Medical University, Shandong Province, Yantai 264003, China;
3.Graduate School, Shandong First Medical University, Shandong Province, Taian 271000, China;
4.Department of Endocrinology, Liaocheng People’s Hospital, Shandong Province, Liaocheng 252000, China |
|
|
Abstract Objective To study the components and targets of Ganjiang Huangqin Huanglian Renshen Decoction in the treatment of gastric adenocarcinoma based on weighted gene co-expression network analysis (WGCNA) and molecular docking. Methods The drug-related components and targets were screened from the traditional Chinese medicine systems pharmacology database and analysis platform, and drug-compound-target interaction network was constructed. Gastric adenocarcinoma gene expression data were downloaded from TCGA database, and the key modules related to the risk level of gastric adenocarcinoma were screened. The biological functions of genes contained in the key modules were analyzed by GO and KEGG database. The module genes were uploaded to STRING database to screen key targets, and the semi-flexible docking reverse verification of key targets was carried out by molecular docking technology. Results Fifty-nine active components and 184 targets were screened, and 242 nodes and 676 edges were obtained from drug-compound-target interaction network. The key modules screened by WGCNA included 32 genes in total. The results of GO and KEGG enrichment mainly involve DNA integrity test points, reaction to metal ions, p53 signaling pathway, cell cycle, and cell senescence, etc. The key targets were VEGFA, CDK1, and CCND1. The molecular docking showed that quercetin, baicalein, baicalein, and other compounds had higher binding activities with key targets. Conclusion A variety of active ingredients can combine with the targets of gastric adenocarcinoma to play a regulatory role.
|
|
|
|
|
[1] Cutsem EV,Sagaert X,Topal B,et al. Gastric cancer [J]. Lancet,2016,388(10060):2654-2664.
[2] 卢存存.中药治疗胃癌的研究证据评价及网络药理学研究[D].兰州:兰州大学,2020.
[3] 董智平,张静喆.中医治疗胃癌研究进展[J].中国中西医结合外科杂志,2019,25(2):206-209.
[4] 亓雪,张颖颖.干姜的化学、药理研究进展[J].山东化工,2018,47(14):41-42.
[5] 李怡萍,张春蕾,徐娇雅,等.黄芩苷抗肿瘤作用机制研究进展[J].中医学,2021,10(1):101-106.
[6] 付琳,付强,李冀,等.黄连化学成分及药理作用研究进展[J].中医药学报,2021,49(2):87-92.
[7] 高健,吕邵娃.人参化学成分及药理作用研究进展[J].中医药导报,2021,27(1):127-130,137.
[8] 郑潇豪.加权基因共表达网络(WGCNA)在探索胃腺癌预后相关基因中的运用[D].北京:北京协和医学院,2020.
[9] 王一迪,唐尊昊.《伤寒论》上热下寒证5首经方浅析[J].中国民间疗法,2020,28(11):19-21.
[10] 杨楠,贾晓斌,张振海,等.黄酮类化合物抗肿瘤活性及机制研究进展[J].中国中药杂志,2015,40(3):373.
[11] 耿威,仉慧颖,李林,等.槲皮素对胃癌细胞增殖及侵袭的调控作用及机制[J].中国老年学杂志,2018,38(1):34-36.
[12] 王丽君,戴志升.山奈酚对胃癌细胞PARP1以及P53基因表达的影响研究[J].基因组学与应用生物学,2020, 39(3):1270-1274.
[13] 宋海彬.山柰酚在体内和体外抑制胃癌生长的实验研究[D].哈尔滨:哈尔滨医科大学,2016.
[14] 王梓萱,周静,唐玥,等.槲皮素诱导肿瘤细胞P53非依赖的G2/M周期阻滞和凋亡[J].中国药理学与毒理学杂志,2018,32(10):790-796.
[15] 张永海.汉黄芩素体外对胃癌SGC-7901细胞增殖、迁移和侵袭的实验性研究[J].中国比较医学杂志,2019, 29(2):89-95.
[16] 魏友芬.ELTD1、VEGF、DLL4在胃腺癌中的表达及临床意义[D].兰州:兰州大学,2018.
[17] 刘雯静,秦长江.VEGF/VEGFR通路在胃癌靶向治疗中的研究进展[J].河南大学学报:医学版,2021,40(1):68-72.
[18] 赵璐,杜小明.血管内皮生长因子和性别决定区Y框蛋白2在胃癌中的表达及与预后的关系[J].安徽医药,2020,24(4):746-750,852.
[19] 王传光,周建伟,高丽娟,等.全麻下高龄患者腹腔镜胃癌根治术血VEGF变化对术后POCD发生的影响[J].中国现代医生,2021,59(16):130-133.
[20] 戴勇.VEGF-C表达及基因多态性与胃癌的相关性研究[D].济南:山东大学,2017.
[21] 傅华,于爱军,陈凯,等.CDC25A与CDK1在胃癌组织中的表达及其临床意义[J].河北医学,2018,24(1):80-83.
[22] 王晓明,梁国栋,杨玉波,等.CyclinB2、CDK1在胃癌中的表达水平及生物学意义[J].中国老年学杂志,2015, 35(10):2648-2650.
[23] 夏丹.胃癌组织中Nek2、Plk1和Cdk1的表达及意义[J].临床与实验病理学杂志,2014,30(11):1266-1269.
[24] 高琳琳,宋光.CCND1基因多态性与胃癌易感性的关系[J].医学研究杂志,2019,48(1):126-130.
[25] 杨淑敏,师雅琳.CCND1基因多态性与消化系统肿瘤的相关性[J].南方医科大学学报,2016,36(11):1589-1592.
[26] 王妹兴,印季良,肖谜,等.结肠癌组织中miR-340和CCND1表达及临床意义[J].临床肿瘤学杂志,2019,24(6):538-542. |
|
|
|